期刊文献+

一种构建改形单域抗体的方法(英文) 被引量:3

A Method for Constructing Reshaping Single-Domain Antibody
下载PDF
导出
摘要 为验证一种构建改形单域抗体的实用新方法 ,与以往方法不同的是 ,该方法不需要对抗体进行空间结构模拟 ,以确定人源抗体的FRs接受序列及在人源FRs接受序列中哪些氨基酸残基需要突变 ,并且该方法将抗体的改形与亲和力成熟于同一过程完成。利用该方法构建了改形抗CD2 8重链单域抗体。根据一种鼠源抗CD2 8重链单域抗体的氨基酸序列 ,于GenBank中查得两条与之最同源的人源抗体序列 ,利用其中一条的FRs作为改形抗体的主框架进行改形构建。将鼠源抗体的CDR区插入到人源FR区后 ,对人源FR区的一些氨基酸残基进行替换突变 ,替换的氨基酸残基数及替换原则主要是根据对查到的人源抗体序列、鼠源抗体序列 ,以及这些序列与Kabat分类中的种属序列进行的比较。为了增加改形抗体基因的多样性 ,对要被替换的氨基酸残基在基因合成中采用简并的方式 ,使要被替换的氨基酸残基和替换的氨基酸残基都有机会出现 ,二者出现的几率各为 5 0 %。同时 ,在将大小不同的合成核苷酸片段采用重叠PCR扩增以获得完整改形抗体基因时 ,采用高Mg2 + 浓度下和使用TaqDNA聚合酶 ,以进一步随机引入突变。利用重叠PCR产物构建了一个噬菌体抗体库 ,经过 3轮淘选后 ,获得了几个具有较高免疫学活性的改形抗体。对其中的两个抗体进行了进一步研究 ,将? The aim of this research was to demonstrate a novel and practical method for constructing reshaping Single domain antibodies. Different from other methods, our method does not need to model the configuration of antibodies with specific sequences to determine the sequences of human acceptor FRs and then determine which amino acid residues in human acceptor FRs should be substituted. Most importantly, reshaping and enhancing the antigen binding affinity shared one procedure at the same time. Using this method, the reshaping anti CD28 single domain antibodies were constructed. According to the amino acid sequence of a mouse anti human CD28 monoclonal antibody VH, two most homologous sequences of human antibodies were selected from GenBank and one of them was used as a main framework region for constructing the reshaping antibody. Before the original mouse antibody CDRs were inserted into the human acceptor FRs, some amino acid residues which were different from those of the original mouse antibody in the corresponding positions ofthe human acceptor FRs were determined or alternatively mutated by their conservative properties in Kabat classification. When the synthesized nucleotide fragments in different length were spliced by overlap PCR into the entire reshaping genes, Taq DNA polymerase and high Mg 2+ concentration were used to introduce more mutation in FRs and CDRs randomly. A phage library was constructed using these PCR products and several reshaping Single domain antibodies with high antigen binding affinity were selected after three rounds of panning. Two of them were expressed in E. coli BL21(DE3). The antigen binding affinity of refolded proteins was still in a high level measured by ELISA. These results suggested that this method was feasible and efficient for constructing reshaping Single domain antibodies.
出处 《Acta Genetica Sinica》 SCIE CAS CSCD 北大核心 2002年第3期189-195,共7页
基金 TheprojectwassupportedbytheNational"863"Hi TechDevelopmentPlanofChina (grantNo .863 10 2 0 9 0 4 0 1)
关键词 定向分子进化 CD28 改形重链单域抗体 可选择突变 随机突变 噬菌体展示 免疫学活性 directed molecular evolution CD28: reshaping Single domain antibody alternative mutation random mutation phage display antigen binding affinity
  • 相关文献

参考文献1

二级参考文献2

  • 1Moore J C,J Mol Biol,1997年,272卷,336页
  • 2Kabat E A,NIH Bethesda,1991年,91页

共引文献3

同被引文献47

  • 1王琰.抗体库技术[J].单克隆抗体通讯,1993,9(3):23-25. 被引量:6
  • 2[9]Turner DJ, Ritter MA, George AJT, et al. Importance of the linker in expression of single chain Fv antibody fragments:optimization of pepitide sequence using phage display technology[J]. Immunol Methods, 1997,205(1) :43 - 54.
  • 3[10]Hennecke F, Krebber C, Pluckthum A, et al. Non-repetitive single-chain Fv linkers selectively infective phage(SIP) technology[J]. Protein Eng, 1998,11 (5) :405 - 410.
  • 4GilBoa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother, 1999, 48(7):382-385.
  • 5Zhu Z, Lewis GD, Carter P. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab') 2 for efficient lysis of p185HER2 overexpressing tumor cells. Int J Cancer, 1995, 62(3):319-324.
  • 6Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH et al. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother, 1993, 37(6):400-407.
  • 7Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk I, Repp r, Deo YM et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood, 1997, 90(11):4485-4492.
  • 8Segal DM, Weiner GJ, Weiner LM. Introduction: Bispecific antibodies. J Immunol Methods, 2001, 248(1-2):1-6.
  • 9Salomon B, Bluestone JA. Complexities of CD28/BT: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol, 2001, 19:225-252.
  • 10Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol, 2002, 2(2):116-126.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部